JPWO2020243448A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020243448A5
JPWO2020243448A5 JP2021570756A JP2021570756A JPWO2020243448A5 JP WO2020243448 A5 JPWO2020243448 A5 JP WO2020243448A5 JP 2021570756 A JP2021570756 A JP 2021570756A JP 2021570756 A JP2021570756 A JP 2021570756A JP WO2020243448 A5 JPWO2020243448 A5 JP WO2020243448A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence
actriib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021570756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534966A (ja
JP7669291B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035148 external-priority patent/WO2020243448A1/en
Publication of JP2022534966A publication Critical patent/JP2022534966A/ja
Publication of JPWO2020243448A5 publication Critical patent/JPWO2020243448A5/ja
Priority to JP2025067310A priority Critical patent/JP2025118664A/ja
Application granted granted Critical
Publication of JP7669291B2 publication Critical patent/JP7669291B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021570756A 2019-05-30 2020-05-29 Ａｃｔｒｉｉ結合性タンパク質及びその使用 Active JP7669291B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025067310A JP2025118664A (ja) 2019-05-30 2025-04-16 Ａｃｔｒｉｉ結合性タンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962854625P 2019-05-30 2019-05-30
US62/854,625 2019-05-30
PCT/US2020/035148 WO2020243448A1 (en) 2019-05-30 2020-05-29 Actrii-binding proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025067310A Division JP2025118664A (ja) 2019-05-30 2025-04-16 Ａｃｔｒｉｉ結合性タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2022534966A JP2022534966A (ja) 2022-08-04
JPWO2020243448A5 true JPWO2020243448A5 (enExample) 2023-06-06
JP7669291B2 JP7669291B2 (ja) 2025-04-28

Family

ID=73553540

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021570756A Active JP7669291B2 (ja) 2019-05-30 2020-05-29 Ａｃｔｒｉｉ結合性タンパク質及びその使用
JP2025067310A Pending JP2025118664A (ja) 2019-05-30 2025-04-16 Ａｃｔｒｉｉ結合性タンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025067310A Pending JP2025118664A (ja) 2019-05-30 2025-04-16 Ａｃｔｒｉｉ結合性タンパク質及びその使用

Country Status (8)

Country Link
US (1) US20220242956A1 (enExample)
EP (1) EP3976630A4 (enExample)
JP (2) JP7669291B2 (enExample)
KR (1) KR20220029563A (enExample)
CN (1) CN114127087A (enExample)
AU (1) AU2020284038A1 (enExample)
CA (1) CA3142149A1 (enExample)
WO (1) WO2020243448A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250064952A1 (en) * 2021-03-10 2025-02-27 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
WO2022192404A1 (en) * 2021-03-10 2022-09-15 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
MX2024002711A (es) * 2021-09-03 2024-05-02 Laekna Therapeutics Shanghai Co Ltd Anticuerpos de receptor de activina tipo-2a (anti-acvr2a) y usos de estos.
WO2025027052A1 (en) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
TW202513591A (zh) * 2023-08-01 2025-04-01 大陸商來凱醫藥科技（上海）有限公司 抗acvr2b抗體及其用途
AR133979A1 (es) * 2023-09-28 2025-11-19 Sixpeaks Bio Ag ANTICUERPOS DIRIGIDOS A ActRIIA Y ActRIIB

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002567A1 (es) * 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
GR1007832B (el) * 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
WO2013188448A2 (en) * 2012-06-11 2013-12-19 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
WO2014172448A2 (en) 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
TWI655207B (zh) * 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
PT3286206T (pt) * 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
JP7058606B2 (ja) 2016-02-22 2022-04-22 アクセルロン ファーマ インコーポレイテッド 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト
KR102866147B1 (ko) * 2016-03-10 2025-09-30 악셀레론 파마 인코포레이티드 액티빈 타입 2 수용체 결합 단백질 및 이의 용도
JP7339159B2 (ja) * 2017-03-24 2023-09-05 ノバルティス アーゲー 心疾患の予防および治療方法

Similar Documents

Publication Publication Date Title
JP6585503B2 (ja) ヘテロ二量体免疫グロブリン
JP2024026159A5 (enExample)
CN102037016B (zh) 针对粒细胞巨噬细胞集落刺激因子的抗体
JP2019513015A5 (enExample)
JP7766392B2 (ja) 治療用抗ｃｄ４０リガンド抗体
WO2019195313A1 (en) Anti-vegf antagonist and pedf agonist constructs and uses thereof
JP2019515676A5 (enExample)
TW202221043A (zh) PD-1/TGF-beta四價雙特異性抗體、其製備方法和用途
JP2021500895A5 (enExample)
WO2019080909A1 (en) TARGETING THERAPEUTIC ANTIBODY RANKL
EP3577136A1 (en) Inhibition of platelet aggregation using anti-human gpvi antibodies
US12473367B2 (en) Bispecific agonistic antibodies to activin a receptor like type 1 (ALK1)
JPWO2020243448A5 (enExample)
JP2023535840A (ja) 抗原結合タンパク質
CN115811987A (zh) 抗神经酰胺抗体
JPWO2020243443A5 (enExample)
JPWO2022253314A5 (enExample)
TW202523697A (zh) 抗ｔｓｌｐ抗體構築體及其用途
TW202409093A (zh) 融合蛋白